IP Library Patent Application 14832163
Patent Application
App. No. 14/832,163

Method and System for Treatment of Damaged Biological Tissue

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/832,163
Abstract

Biomaterial compositions and articles comprising extracellular matrix (ECM) and an ECM-mimicking biomaterial, such as poly(glycerol sebacate) (PGS), for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions and articles can also include additional biologically active agents, such as growth factors, and polymeric materials, such as polyepsilon-caprolactone (PCL).

Claims (22)

1 . A particulate composition for treating damaged biological tissue, comprising:

a plurality of particulate components comprising an extracellular matrix (ECM) composition, said ECM composition comprising at least one acellular ECM material, each of said plurality of particulate ECM components being encased in an ECM-mimicking biomaterial composition, said particulate composition being configured to induce modulated healing when delivered to damaged biological tissue, said modulated healing comprising modulation of inflammation of said damaged tissue, and induced cell proliferation and bioremodeling of said tissue.

2 . The composition of claim 1 , wherein said particulate composition further comprises a buffer solution.

3 . The composition of claim 2 , wherein said particulate composition has a concentration of said plurality of particulate components in the range of 0.001-200 mg/ml.

4 . The composition of claim 1 , wherein said ECM-mimicking biomaterial composition comprises poly(glycerol sebacate) (PGS).

5 . The composition of claim 1 , wherein said ECM material comprises ECM from a mammalian tissue source selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), mesothelial tissue, subcutaneous extracellular matrix, gastrointestinal extracellular matrix, placental extracellular matrix, omentum extracellular matrix, cardiac extracellular matrix, kidney extracellular matrix, pancreas extracellular matrix, lung extracellular matrix, and combinations thereof.

6 . The composition of claim 1 , wherein said ECM-mimicking biomaterial composition further comprises a polymer selected from the group consisting of polyglycolide (PGA), polylactide (PLA), polyepsilon-caprolactone (PCL), poly dioxanone, poly lactide-co-glycolide, polyamide esters, polyalkalene esters, polyvinyl esters, polyvinyl alcohol, and polyanhydrides.

7 . The composition of claim 6 , wherein said polymer comprises PCL

8 . The composition of claim 1 , wherein said ECM composition further comprises an exogenously added biologically active agent.

9 . The composition of claim 8 , wherein said biologically active agent comprises a growth factor is selected from the group consisting of transforming growth factor alpha (TGF-α), transforming growth factor beta (TGF-β), fibroblast growth factor-2 (FGF-2), basic fibroblast growth factor (bFGF), vascular epithelial growth factor (VEGF), and insulin-like growth factor (IGF).

10 . The composition of claim 8 , wherein said biologically active agent comprises a cell selected from the group consisting of an embryonic stem cell, mesenchymal stem cell, hematopoietic stem cell, bone marrow stem cell, bone marrow-derived progenitor cell, myosatellite progenitor cell, totipotent stem cell, pluripotent stem cell, multipotent stem cells, oligopotent stem cell and unipotent stem cell.

11 . The composition of claim 8 , wherein said biologically active agent comprises a protein selected from the group consisting of collagen (types I-V), proteoglycans, glycosaminoglycans (GAGs), glycoproteins, cytokines, cell-surface associated proteins, and cell adhesion molecules (CAMs).

12 . The composition of claim 8 , wherein said biologically active agent comprises statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.

13 . The composition of claim 1 , wherein said ECM composition further comprises a pharmacological agent.

14 . The composition of claim 13 , wherein said pharmacological agent comprises an agent selected from the group consisting of an anti-viral agent, analgesic, antibiotic, anti-inflammatory, anti-neoplastic, anti-spasmodic, enzyme and enzyme inhibitor, anticoagulant and/or antithrombic agent, and vasodilating agent.

15 . The composition of claim 1 , wherein said ECM-mimicking biomaterial composition further comprises an exogenously added biologically active agent.

16 . The composition of claim 15 , wherein said biologically active agent comprises a growth factor is selected from the group consisting of transforming growth factor alpha (TGF-α), transforming growth factor beta (TGF-β), fibroblast growth factor-2 (FGF-2), basic fibroblast growth factor (bFGF), vascular epithelial growth factor (VEGF), and insulin-like growth factor (IGF).

17 . The composition of claim 15 , wherein said biologically active agent comprises a cell selected from the group consisting of an embryonic stem cell, mesenchymal stem cell, hematopoietic stem cell, bone marrow stem cell, bone marrow-derived progenitor cell, myosatellite progenitor cell, totipotent stem cell, pluripotent stem cell, multipotent stem cells, oligopotent stem cell and unipotent stem cell.

18 . The composition of claim 15 , wherein said biologically active agent comprises a protein selected from the group consisting of collagen (types I-V), proteoglycans, glycosaminoglycans (GAGS), glycoproteins, cytokines, cell-surface associated proteins, and cell adhesion molecules (CAMs).

19 . The composition of claim 15 , wherein said biologically active agent comprises statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.

20 . The composition of claim 1 , wherein said ECM-mimicking biomaterial composition further comprises a pharmacological agent.

21 . The composition of claim 20 , wherein said pharmacological agent comprises an agent selected from the group consisting of an anti-viral agent, analgesic, antibiotic, anti-inflammatory, anti-neoplastic, anti-spasmodic, enzyme and enzyme inhibitor, anticoagulant and/or antithrombic agent, and vasodilating agent.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jun 2, 2017
From: MIDCAP FINANCIAL TRUST
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 042669/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2016
From: MATHENY, ROBERT G
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 037761/0833 →
SECURITY INTEREST Recorded Sep 30, 2015
From: CORMATRIX CARDIOVASCULAR, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 036732/0103 →